Travere Presents Phase 3 FILSPARI Biomarker Data in IgA Nephropathy
Travere Therapeutics presented Phase 3 PROTECT study data at ASN Kidney Week, indicating that FILSPARI (sparsentan) may modify disease pathophysiology in IgA nephropathy patients. The global, double-blind trial compared FILSPARI against irbesartan in 404 adults. Results at Week 110 demonstrated greater least-squares mean percentage changes from baseline, normalized to urine creatinine, in the FILSPARI cohort, though researchers noted these p values were nominal.
Travere Therapeutics, Inc. presented new biomarker data from the Phase 3 PROTECT Study at ASN Kidney Week. The findings provide evidence suggesting that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN).
PROTECT was a global, randomized, multicenter, double-blind and active-controlled Phase 3 clinical trial involving 404 adults with IgAN. The study evaluated the safety and efficacy of FILSPARI compared with irbesartan.
At Week 110, the least-squares mean percentage changes from baseline, normalized to urine creatinine, were greater among patients receiving FILSPARI than among those receiving irbesartan. Travere noted that the reported p values were nominal.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.